OncLive TV

Elias Jabbour, MD, discusses the significance of the FDA approval of orally disintegrating nilotinib tablets for chronic myeloid leukemia.

Toni Choueiri, MD, discusses how he will utilize adjuvant belzutifan plus pembrolizumab in ccRCC after its FDA approval.

Alexey Danilov, MD, PhD, discusses DAYBreak CLL-201 and how it plans to evaluate bexobrutideg in chronic lymphocytic leukemia.

Matthew S. Davids, MD, MMSc, discusses how efficacy data for pirtobrutinib plus venetoclax and rituximab from BRUIN CLL-322 may affect relapsed/refractory CLL management.

Praful Ravi, MB, BChir, MRCP, discusses the design of the PSMAtrack study of changes in PSMA-PET during initial therapy in patients with mHSPC.

Alan L. Ho, MD, PhD, discusses an upcoming phase 3 trial evaluating Oz-V in OPSCC and key aspects of its design.

Praful Ravi, MB, BChir, MRCP, discusses the clinical utility of PSMA-PET in mHSPC.

Tanios S. Bekaii-Saab, MD, discusses FIGHT-302 data showing frontline pemigatinib significantly improves PFS in FGFR2-positive cholangiocarcinoma.

Praful Ravi, MB, BChir, MRCP, discusses data from the phase 4 PSMAtrack trial in mHSPC.

Andrew Spencer, MBBS, FRACP, FRCPA, DM, discusses the potential role for in vivo CAR T-cell therapy in relapsed/refractory multiple myeloma.

Tanios S. Bekaii-Saab, MD, discusses the clinical significance of the FDA approval of zenocutuzumab for NRG1 fusion–positive CCA.

Nirav N. Shah, MD, MSHP, discusses the design of DAYBreak CLL-201 and its potential importance for chronic lymphocytic leukemia management.

Andrew Spencer, MBBS, FRACP, FRCPA, DM, discusses efficacy data for the in vivo CAR T-cell therapy KLN-1010 in multiple myeloma.

Andrew Spencer, MBBS, FRACP, FRCPA, DM, discusses key features of in vivo CAR T-cell therapy in multiple myeloma.

Prithviraj Bose, MD, discusses the ongoing investigation of sapablursen in polycythemia vera.

Ruta D. Rao, MD, discusses a prospective sub-study of the PARTNER trial evaluating the effect of ctDNA status on distant recurrence in early TNBC.

Christian Grommes, MD, discusses how BTK inhibitors and CAR T-cell therapy fit into the relapsed/refractory primary CNS lymphoma treatment paradigm.

Everett Meyer, MD, PhD, discusses the significance of the FDA approval of Orca-T for patients with hematologic malignancies.

R. Lor Randall, MD, FACS, reviews the prognostic potential and current clinical limitations of personalized ctDNA panels in osteosarcoma.

Claire Harrison, MD, details the implications of the INDEPENDENCE trial data for luspatercept in myelofibrosis-associated anemia.

Charles E. Geyer, MD, discusses the significance of the FDA approval of neoadjuvant T-DXd followed by THP for patients with HER2-positive breast cancer.

Charles E. Geyer, MD, highlights data that led to the FDA approval of post-neoadjuvant T-DXd for patients with HER2-positive breast cancer.

Pankit Vachhani, MD, discusses data that have read out for sapablursen in the treatment of patients with polycythemia vera.

Sikander Ailawadhi, MD, discusses the ongoing evaluation of cemsidomide in relapsed/refractory multiple myeloma.

At the 6th World Congress of Cutaneous Lymphoma, a group of world-leading CTCL expert consider what the field will abandon in the next decade.

Robert Stein, MBBS, PhD, discusses the background and design of the OPTIMA trial of test-directed chemotherapy in ER-positive, HER2-negative early breast cancer.

Marwan G. Fakih, MD, explains why obtaining a liquid biopsy at diagnosis is critical to avoid uninformative genomic results after starting chemotherapy.

Robert Stein, MBBS, PhD, discusses the data from the OPTIMA trial in ER+, HER2-negative early breast cancer and the trial's key clinical implications.

R. Lor Randall, MD, FACS, discusses how ctDNA could be used to identify microscopic residual disease in patients who appear radiographically disease-free.

Jacob Stephen Thomas, MD, discussed the efficacy of first-line ipatasertib plus pembrolizumab in patients with recurrent or metastatic HNSCC.